-
2022-501183-17-00
7
2023-02-23
Non-Small Cell Lung Cancer
-
2023-503793-20-00
5
2023-01-18
Prevention of ischemic stroke in patients post acute non-cardioembolic
-
2023-510195-31-00
4
2023-01-03
Idiopathic or Diabetic Gastroparesis
-
2023-503794-38-00
5
2022-11-24
Prevention of stroke or systemic embolism in atrial fibrillation
-
2024-514714-12-00
10
2022-11-11
Metastatic Pancreatic Ductal Adenocarcinoma
-
2023-506981-30-00
4
2022-05-25
Chronic kidney disease in type 2 diabetes mellitus
-
2023-506278-10-00
5
2022-04-22
Eosinophilic esophagitis
-
2024-514570-43-00
5
2022-01-24
Renal cell carcinoma
-
2023-506170-12-00
4
2021-10-18
Alzheimer’s Disease
-
2023-506897-11-00
5
2021-10-18
Non-diabetic chronic kidney disease
-
2023-506926-35-00
5
2021-09-24
Atherosclerotic cardiovascular disease, chronic kidney disease and sys
-
2023-508340-22-00
4
2021-08-11
metastatic or unresectable, recurrent HNSCC
-
2023-508342-17-00
4
2021-08-11
metastatic or unresectable, recurrent HNSCC
-
2024-511481-37-00
4
2021-07-12
Previously Treated, Locally-Advanced Unresectable or Metastatic Solid
-
2023-506918-45-00
5
2021-05-17
Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
-
2023-506919-18-00
5
2021-05-17
Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
-
2024-511140-37-00
4
2021-02-12
OligoRecurrent prostate cancer
-
2024-517429-24-00
7
2020-01-09
Non-small-cell lung cancer
-
2023-509061-20-00
9
2018-11-22
Advanced solid tumors
-
2023-510189-28-00
6
2018-05-15
Rheumatoid Arthritis
-
2023-509595-42-00
5
2017-10-31
Gastric and gastroesophageal junction (GEJ) adenocarcinoma
-
2022-501353-37-00
5
Reversal of anticoagulation effect in patients on a FXa inhibitor (api